Loading…
OPRX
OptimizeRx Corp
NASDAQ· Healthcare· Health Information Services· CUSIP 68401U204
$8.50-3.95%Price as of Oct 17, 12:02 UTC · updated once a day, after the close
At a glance
OptimizeRx Corp (OPRX) is listed on NASDAQ and classified in Health Information Services, part of the Healthcare sector. It is headquartered in Waltham, United States and has 132 employees. The company is worth $160.11M and trades at 35.4x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $109.43M in fiscal 2025, up 18.8% from the year before. Net income was $5.13M. The share price is 61.8% below its 52-week high of $22.25. 5 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Cliff Asness (AQR Capital Management), at $3.34M. In that quarter, 1 of them opened or added to the position. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $160.11M
- P/E
- 35.4x
- Forward P/E
- 8.1x
- P/B
- 1.2x
- Dividend yield
- 0.00%
- Payout
- —
- EPS
- $0.24
- ROE
- 3.67%
- Profit margin
- 4.66%
- Revenue growth
- -29.80%
- Beta
- 1.26
- 52-week high
- $22.25
- 52-week low
- $4.54
History
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -86.9% over 5Y.
today you would have $87.90▼ -91.2%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 16 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $12.26 | $4.86 | $14.31 | $16.80 | $62.11 | $31.16 | $10.27 | $10.97 | $4.71 | $2.43 | $3.66 | $3.54 | $5.10 | $3.18 | $2.67 | $2.46 | |
| P/E | — | 45.4x |
Fair price, seven ways
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Earnings
$6.13
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings
$6.00
Earnings growing 25.0% a year plus a 0.0% dividend yield. Growth capped at 25%.
Earnings
$5.83
Median P/E of 24.3 among peers in the sector.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow
$33.84
Cash flow growing 15.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Operating
$11.85
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
Dividends
—
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| IPHAInnate Pharma SA | $1.43 | — | — | 0.00% | — | $159.73M |
| DTILPrecision Biosciences Inc | $5.77 | — | 3.4x | 0.00% | -135.15% | $159.26M |
| CHRSCoherus Oncology, Inc. | $1.05 | — | 2.7x | 0.00% | -178.39% | $162.23M |
| VRXAVeraxa Biotech AG - Post de-SPAC | $1.11 |
About the company
- 132
- Waltham, United States